Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (131-140 of 357) with videos related to

Pageof 36
Sort By:
Current Opinion in Oncology|February 8, 2006
Antiangiogenic drugs in non-small cell lung cancer treatmentTina Cascone, Teresa Troiani, Maria Pia Morelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2007
Lung cancer in the elderlyCesare Gridelli, Corey Langer, Paolo Maione, et al.
Expert Opinion on Biological Therapy|February 21, 2023
Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancerDanilo Rocco, Luigi Della Gravara, Ciro Battiloro, et al.
Clinical Lung Cancer|June 15, 2007
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamicsCesare Gridelli, Antonio Rossi, Floriana Mongillo, et al.
Cancer Treatment Reviews|May 22, 2009
Management of unfit older patients with advanced NSCLCCesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2012
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxelMassimo Di Maio, Maciej Krzakowski, Ronan Fougeray, et al.
Critical Reviews in Oncology/Hematology|June 23, 2004
The role of targeted therapy in non-small cell lung cancerPaolo Maione, Antonio Rossi, Giuseppe Airoma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Reply to S. Barni et Al, K.R. Dearing et al, and N. MurrayLuis G Paz-Ares, Filippo de Marinis, Carla Visseren-Grul, et al.
Reviews on Recent Clinical Trials|September 11, 2008
The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancerAntonio Rossi, Emilio Bria, Paolo Maione, et al.
Lung Cancer (Amsterdam, Netherlands)|March 29, 2011
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelinesFilippo de Marinis, Antonio Rossi, Massimo Di Maio, et al.
Pageof 36

Showing results (131-140 of 357) with videos related to

Sort By:
Pageof 36
Current Opinion in Oncology|February 8, 2006
Antiangiogenic drugs in non-small cell lung cancer treatmentTina Cascone, Teresa Troiani, Maria Pia Morelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2007
Lung cancer in the elderlyCesare Gridelli, Corey Langer, Paolo Maione, et al.
Expert Opinion on Biological Therapy|February 21, 2023
Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancerDanilo Rocco, Luigi Della Gravara, Ciro Battiloro, et al.
Clinical Lung Cancer|June 15, 2007
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamicsCesare Gridelli, Antonio Rossi, Floriana Mongillo, et al.
Cancer Treatment Reviews|May 22, 2009
Management of unfit older patients with advanced NSCLCCesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2012
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxelMassimo Di Maio, Maciej Krzakowski, Ronan Fougeray, et al.
Critical Reviews in Oncology/Hematology|June 23, 2004
The role of targeted therapy in non-small cell lung cancerPaolo Maione, Antonio Rossi, Giuseppe Airoma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Reply to S. Barni et Al, K.R. Dearing et al, and N. MurrayLuis G Paz-Ares, Filippo de Marinis, Carla Visseren-Grul, et al.
Reviews on Recent Clinical Trials|September 11, 2008
The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancerAntonio Rossi, Emilio Bria, Paolo Maione, et al.
Lung Cancer (Amsterdam, Netherlands)|March 29, 2011
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelinesFilippo de Marinis, Antonio Rossi, Massimo Di Maio, et al.
Pageof 36